It is not long since the treatment opportunities of metastatic prostate cancer have been introduced to mankind
It is not long since the treatment opportunities of metastatic prostate cancer have been introduced to mankind. In such revolutionary period many non-hormonal & hormonal agents like Enzalutamide have been incorporated as a vital treatment alternative for prostate cancer and with the use of Enzalutamide the overall patient survival rate went up than other therapeutic agents. Being a non-steroidal 2nd generation anti-androgen it was approved for the treatment of metastatic CRPC, even if it was employed in post-docetaxel and chemotherapy-naïve setting. In this study the pharmacological peculiarities of enzalutamide, the efficacy studies which made it possible to approve this anti-androgen as well as its place in the consecutive treatment of metastatic prostate cancer is discussed here.